Good news, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved eplontersen (also known as Wainua) for the treatment of polyneuropathy associated with hereditary transthyretin amyloidosis (ATTRv-PN).
This approval, announced on October 16, 2024, marks a crucial advancement in managing this debilitating and progressive condition.
What is Hereditary Transthyretin Amyloidosis?
Understanding the Condition
Hereditary transthyretin amyloidosis (ATTRv-PN) is a rare genetic disorder caused by mutations in the transthyretin (TTR) gene. This mutation leads to the misfolding of the TTR protein, which accumulates as amyloid fibrils in peripheral nerves, causing severe nerve damage and motor disability.
Without treatment, this condition is generally fatal within a decade of diagnosis.
How Does Eplontersen Work?
Mechanism of Action
Eplontersen is a ligand-conjugated antisense oligonucleotide (LICA) designed to reduce the production of the TTR protein. By targeting the mRNA responsible for TTR production, eplontersen significantly lowers serum TTR levels, thereby reducing the accumulation of amyloid fibrils in tissues.
This mechanism has shown promising results in clinical trials, with patients experiencing less neuropathy impairment and improved quality of life.
Clinical Trial Outcomes
NEURO-TTRansform Trial
The NEURO-TTRansform Phase III trial, which enrolled 168 patients with ATTRv-PN, demonstrated the efficacy and safety of eplontersen.
The trial showed a significant reduction in serum TTR levels (−81.7% vs −11.2% in the placebo group) and improved neuropathy symptoms.
Patients treated with eplontersen also reported better quality of life compared to the historical placebo group.
Takeaways
- MHRA Approval: Eplontersen has been approved by the UK’s MHRA for treating adults with ATTRv-PN.
- Mechanism: Reduces TTR protein production through antisense oligonucleotide technology.
- Clinical Benefits: Significantly lowers serum TTR levels, reduces neuropathy impairment, and improves quality of life.
- Administration: Can be self-administered via an auto-injector, a first for ATTRv-PN treatments.
- Global Impact: Part of a global development and commercialization agreement between AstraZeneca and Ionis Pharmaceuticals.
Impact on Patients and Families
The approval of eplontersen represents a meaningful advancement for patients and families affected by hereditary transthyretin amyloidosis. This treatment offers a new hope for managing the relentless and debilitating effects of the disease.
As Isabelle Lousada, President and CEO of the Amyloidosis Research Consortium, noted,
“People with hereditary transthyretin-mediated amyloid polyneuropathy often face a long and arduous journey to diagnosis. This new treatment is crucial for improving their quality of life”.
Final Thoughts
The MHRA’s approval of eplontersen is a significant milestone in the treatment of hereditary transthyretin amyloidosis.
This new therapy provides a much-needed option for patients suffering from this rare and progressive condition, offering them a chance to manage their symptoms more effectively and improve their quality of life.
As research and development continue, there is growing hope for further innovations in treating this and other forms of amyloidosis.
Sources: THX News & Medicines and Healthcare products Regulatory Agency.
